Previous 10 | Next 10 |
2024-01-31 17:03:58 ET Gainers: Nextracker ( NXT ) +15% . Align Technology ( ALGN ) +11% . EZCORP ( EZPW ) +9% . Protagonist Therapeutics ( PTGX ) +8% . Cimpress ( CMPR ) +8% . Losers: MaxLinear ( MXL ) -8% ...
NEW HAVEN, Conn., Jan. 16, 2024 (GLOBE NEWSWIRE) -- Arvinas, Inc. (Nasdaq: ARVN), a clinical-stage biotechnology company creating a new class of drugs based on targeted protein degradation, today announced that Jared Freedberg, J.D., has joined the company as General Counsel. “We are...
2024-01-06 04:28:00 ET Stock Traders Daily has produced this trading report using a proprietary method. This methodology seeks to optimize the entry and exit levels to maximize results and limit risk, and it is also applied to Index options, ETFs, and futures for our subscribers. This...
2023-12-19 13:36:10 ET More on Arvinas Arvinas: Positive Breast Cancer Data Leads To Other Developments Arvinas: Protein Degradation Pioneer Presents An Intriguing Speculative Buy Opportunity Jefferies upgrades Arvinas to buy in wake of positive ARV-471 data ...
2023-12-15 16:20:04 ET Summary Positive interim data achieved by Arvinas, Inc. from phase 1b study using vepdegestrant for the treatment of patients with ER+/HER2- advanced or metastatic breast cancer patients respectively. Two ongoing phase 3 studies being advanced are using vepd...
2023-12-08 09:48:00 ET More on Arvinas Jefferies upgrades Arvinas to buy in wake of positive ARV-471 data Arvinas stock jumps 30% amid positive data for breast cancer drug For further details see: Arvinas files to sell 16.39M shares of common stock for holders
2023-12-06 14:00:43 ET More on Arvinas Arvinas: Protein Degradation Pioneer Presents An Intriguing Speculative Buy Opportunity Arvinas stock jumps 30% amid positive data for breast cancer drug Arvinas announces private placement to raise $350M Seeking Al...
2023-12-06 13:41:44 ET More on Arvinas Arvinas: Protein Degradation Pioneer Presents An Intriguing Speculative Buy Opportunity Arvinas announces private placement to raise $350M Arvinas GAAP EPS of -$1.18 beats by $0.39, revenue of $34.6M misses by $5.45M ...
2023-12-06 12:41:58 ET More on Mid-day movers $ stocks. Altimmune: Don't Buy The GLP-1 Move-Up Altimmune: Pemvidutide Data Reinforces Obesity Drug Outlook Syros Pharmaceuticals, Inc. (SYRS) Q3 2023 Earnings Call Transcript Altimmune weight-loss drug performed...
NEW HAVEN, Conn., Dec. 05, 2023 (GLOBE NEWSWIRE) -- Arvinas, Inc. (Nasdaq: ARVN), a clinical-stage biotechnology company creating a new class of drugs based on targeted protein degradation, today announced that a conference call and webcast will be held with executives from Arvinas and Pfizer Inc...
News, Short Squeeze, Breakout and More Instantly...
– Two New Independent Directors, Stuart Duty and Andrew Saik, Appointed – Third New Independent Director to Be Appointed to Board in Near Term MONTREAL and CHARLOTTE, N.C., July 15, 2024 (GLOBE NEWSWIRE) -- Milestone ® Pharmaceuticals Inc. (Nasdaq: MIST) (...
- Awards Mr. Saik an Inducement Grant in accordance with Nasdaq Listing Rule 5635(c)(4) - NEW HAVEN, Conn., June 24, 2024 (GLOBE NEWSWIRE) -- Arvinas, Inc. (NASDAQ: ARVN), a clinical-stage biotechnology company creating a new class of drugs based on targeted protein degradation, today ann...
– Preclinical data for ARV-393 presented at t he European Hematology Association 2024 Annual Congress showed anti-tumor activity in models of B-cell lymphoma – – Preclinical data presented at the Biennial International LRRK2 Meeting high...